Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver.”In the company’s words, NCT07758634 on ClinicalTrials.gov
- Tested for
- Hypertension
- Main trialPhase 1/2
- “A Study of CTX340 in Participants with Uncontrolled Hypertension.”In the company’s words, NCT07758634 on ClinicalTrials.gov
Other drugs for Hypertension
- BaxdrostatAstraZeneca · Phase 3
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- RalinepagUnited Therapeutics · Phase 3
- OrforglipronEli Lilly · Phase 3
- HCP1803-3Hanmi · Phase 3
Coming up1
- 1 Jul 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Jul 2028 | A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026